Passport Capital’s Biolase, Inc. BIOL Stock Holding History

Passport Capital’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-2	Closed	-$50K	–	256
2014 Q1	$50K	Buy	+2	New	+$69.8K	﹤0.01%	198

Other funds holding BIOL

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Passport Capital's BIOL Position: Q2 2014 in Review

Passport Capital sold out of Biolase, Inc. (BIOL) in Q2 2014, closing a stake of 2 shares — an estimated $50K sold.

Passport Capital first reported a position in BIOL in Q1 2014 and held it in 1 quarter. The position peaked at $50K in Q1 2014. 34 funds tracked by Wall St. Rank hold BIOL as of Q2 2014.

Passport Capital reported no remaining Biolase, Inc. position as of Q2 2014 after selling out during the quarter.
Passport Capital sold 2 Biolase, Inc. shares in Q2 2014, an estimated $50K.
Passport Capital first reported a position in Biolase, Inc. in Q1 2014 and held it in 1 quarter.
Passport Capital's Biolase, Inc. position peaked at $50K in Q1 2014.
34 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2014.

Based on Passport Capital's 13F filing for Q2 2014, filed 14 Aug 2014.